Efficacy Observation of Minocycline-Containing Dual Regimen for H. pylori Eradication: An Exploratory Randomized Controlled Clinical Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086342

Enrollment

Unknown

Registered

2024-06-28

Start date

2024-07-01

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

first line treatment control group (VA dual):Vonoprazan 20 mg twice daily + amoxicillin 1.0 g three times daily, for a duration of 14 days

first line treatment test group (VM dual):Vonoprazan 20 mg twice daily + minocycline 100 mg twice daily, for a duration of 14 day

rescue treatment control group (VA dual):Vonoprazan 20 mg twice daily + amoxicillin 1.0 g three times daily, for a duration of 14 days

rescue treatment test group (VM dual):Vonoprazan 20 mg twice daily + minocycline 100 mg twice daily, for a duration of 14 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years, no gender restriction; 2. H. pylori positive (HP positive refers to those with a positive urea breath test within one month prior to enrollment, including untreated individuals and those who previously failed eradication).

Exclusion criteria

Exclusion criteria: 1. Previous use of VA dual regimen or minocycline-containing regimen for H. pylori eradication; 2. Use of antibiotics, bismuth agents, or acid suppressants within 4 weeks prior to treatment; 3. Pregnant or breastfeeding women; 4. Presence of other serious diseases that may affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumors, or alcoholism; 5. Allergy to the study medications (vonoprazan fumarate, amoxicillin, minocycline) or their components; 6. Participation in other drug studies within 3 months prior to using the study medication; 7. Patients unable to accurately express their complaints, such as those with psychosis or severe neurosis, and those unable to cooperate with the trial; 8. Any other conditions deemed unsuitable for participation in this study by the researchers.

Design outcomes

Primary

Measure	Time frame
eradication rate;	—

Secondary

Measure	Time frame
Safety;Side effects;Compliance;	—

Countries

China

Contacts

Public ContactGao Wen

Peking University First Hospital

gaowenhi@163.com+86 136 6117 0535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026